Epizyme identifies novel opportunity for treatment of genetically defined human B-cell lymphomas

Nov 15, 2010

Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, centered on the epigenetic enzyme EZH2, illuminates a clear path for the translation of basic science into targeted therapies for the safe and effective treatment of specific forms of human lymphomas. EZH2 is a histone methyltransferase (HMT), a class of enzymes that play an important role in regulating the activity of particular groups of genes that are involved in serious diseases, including cancer.

The paper describes how the development of two non-Hodgkin lymphomas - and germinal center B-cell like subtype of diffuse large B-cell lymphoma - requires the combined activities of both the wild-type and Tyr641 mutants of EZH2. This novel insight reinforces the development of targeted therapeutics for these patients, as it repudiates the previous supposition that the Tyr641 mutation resulted in a loss of EZH2 function.

Dr. Robert A. Copeland, EVP of R&D and CSO, said, "We believe this is the first example of a human disease that is reliant on the combined catalytic activity of both normal and disease-associated mutant enzymes. By targeting HMTs with clear genetic disease associations, such as EZH2, Epizyme takes a hypothesis-driven approach to development of personalized therapeutics for specific patient populations with high unmet needs. Our product platform enables the creation of novel, potent and selective small molecule HMT inhibitors."

"This paper is a novel, important and representative example of the rapidly growing understanding of the oncogenic role played by HMTs in many cancers. It highlights the promise of HMT inhibitors as novel therapeutics against these targets," said Professor Christopher T. Walsh, the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology (BCMP) at Harvard Medical School and a member of Epizyme's Scientific Advisory Board.

Explore further: Two studies identify a detectable, pre-cancerous state in the blood

More information: The paper, entitled "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas" by Christopher J. Sneeringer, Margaret Porter Scott, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock, Victoria M. Richon, and Robert A. Copeland, will appear in the Proceedings of the National Academy of Sciences during the week of November 15.

Provided by MacDougall Biomedical Communications

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Rheb's role in cancer

Aug 14, 2008

Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.

Small molecule targets B cell lymphoma

Apr 12, 2010

Scientists are one step closer to developing a targeted therapy for lymphoma. New research, published by Cell Press in the April 13th issue of the journal Cancer Cell, identifies a specific small-molecule inhibitor that w ...

New lymphoma therapies targets diverse and difficult cancer

Apr 24, 2008

The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers ...

Recommended for you

Hospital volume not linked to costs of cancer surgery

2 hours ago

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

How a common antacid could lead to cheaper anti-cancer drugs

4 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.